Pneumonia

The grounding supports infectious causes in general, but does not specify particular pathogens or aetiologies. It also includes chemically induced and drug-related lung injury contexts discussed alongside pneumonia-related lung findings, including trastuzumab deruxtecan-related interstitial lung disease/pneumonitis and immune checkpoint inhibitor-related pneumonitis.

Pneumonia involves infection of lung tissue with an inflammatory response. The supplied material also points to pulmonary toxicity and pneumonitis as lung injury syndromes in which diagnosis may require exclusion of other causes, and to dysregulated alveolar macrophage responses after cigarette smoke exposure as a mechanism that can predispose to pulmonary infection and acute lung injury.

Cigarette smoke exposure is identified as a factor that predisposes individuals to pulmonary infection. The grounding also indicates risk in the setting of cancer therapy-associated lung toxicity, including immune checkpoint inhibitors and trastuzumab deruxtecan, though it does not provide broader epidemiologic risk factors for infectious pneumonia.

For community-acquired pneumonia, the supplied guideline abstract supports diagnosis, site-of-care management, antimicrobial therapy, adjunctive surgical therapy in selected cases, and prevention. The corticosteroid review indicates that systemic corticosteroids have been studied as adjunctive therapy to antibiotics, but their role remains unclear, so corticosteroids are not established as routine standard treatment from the supplied grounding.